Loading stock data…
JANX
$14.34-0.03 (-0.21%)
Market ClosedLast close May 1
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Janux Therapeutics, Inc. in the Healthcare sector is trading at $14.34. The stock is currently near its 52-week low of $12.12, remaining 27.5% below its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why JANX maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$14.34
Potential Upside
5%
Whystock Fair Value$15.06
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Mean target$44.13+207.7%
Range$14.00 – $100.00
Fundamentals
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technolo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$933.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.04%
Volume
Today's trading volume
586,164
Recent News
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.
Lilly’s obesity pill off to a strong start; OpenAI debuts new drug discovery tool
Some 1,390 Foundayo prescriptions were written in two days, according to analysts. Elsewhere, multiple biotechs are using OpenAI’s “GPT-Rosalind” and Janux debuted a “double-masked” T cell engager.
Will Health Benefits Weakness Drag Elevance's Q1 Earnings?
ELV heads into its April 22 Q1 report with EPS likely down 11.4% as Health Benefits operating income is projected to plunge 13.7% year over year.
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index down 0.5% an
Sector Update: Health Care Stocks Lower in Afternoon Trading
Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index and the State Str